KeePer Technical Laboratory Co.,Ltd. FY2026 Q3 Earnings Report

Financial Highlights

• Net Sales: ¥18.25B
• Operating Income: ¥4.28B
• Net Income: ¥7.63B
• EPS: ¥279.64

Income Statement

Balance Sheet

Profitability Ratios

Year-over-Year Comparison

Share Information

Dividend Information

Segment Information

Full Year Forecast

---

AI Financial Analysis

Executive Summary

KeePer技研 FY2026 Q3 results show solid topline growth but a sharp deterioration in core profitability, with headline net profit inflated by a large one-off gain. Revenue rose 5.9% YoY to 182.53bn JPY, while operating income fell 20.3% YoY to 42.79bn JPY as gross margin compressed. Gross margin declined to 46.4%, down roughly 600 bps YoY, reflecting higher cost of sales relative to revenue. Operating margin fell to 23.4%, a compression of about 770 bps from the prior year's 31.1%. Ordinary income was 42.91bn JPY (−19.9% YoY), essentially in line with operating profit, indicating minimal recurring non-operating lift. Profit before tax surged to 110.54bn JPY and net income doubled to 76.31bn JPY (+108.5% YoY), entirely driven by 67.63bn JPY of extraordinary income from the sale of investment securities. The net margin expanded to 41.8%, a more than 2,000 bps increase, but this is non-recurring in nature. Segment-wise, KeePer LABO Operation delivered 7.1% sales growth but saw operating income decline 45.3% as its margin compressed to 11.2%, while KeePer Products & Others grew 5.3% with a modest 4.8% decline in operating income and maintained a robust 36.2% margin. SG&A rose 14.1% YoY to 41.86bn JPY, outpacing revenue growth and amplifying operating leverage headwinds. Liquidity is very strong with a current ratio of 339.9% and interest coverage of 313.9x, underpinned by cash and deposits of 132.83bn JPY. The balance sheet deleveraged and de-risked via liquidation of securities (−98.1% YoY) and a 218% increase in cash, while long-term loans declined 40.3%. DuPont ROE printed at 31.8%, driven by an artificially high net margin from extraordinary gains, while asset turnover softened to 0.57. Inventory days rose to 66, signaling working capital tightness to monitor. Against full-year guidance, revenue and operating income progress rates are behind seasonal norms (69% and 59% vs the typical 75%), while net income is ahead (82%) due to the one-off gain. Looking forward, sustaining earnings will require restoring gross and operating margins, especially in the LABO operation, as the extraordinary support will not recur. The company retains ample capacity to invest and support dividends, but execution on margin recovery and inventory management will be key to meeting full-year operating targets.

Profitability Analysis

ROE (31.8%) decomposes into Net Profit Margin (41.8%) × Asset Turnover (0.570) × Financial Leverage (1.33x). The largest driver of change YoY is the net profit margin, which expanded dramatically due to the 67.63bn JPY extraordinary gain on the sale of investment securities. Asset turnover declined versus the prior period as assets grew faster than revenue (notably cash and PPE), dampening operating efficiency. Financial leverage edged down as equity increased with retained earnings, marginally reducing ROE. Operationally, gross margin compressed by roughly 600 bps and operating margin by about 770 bps, reflecting higher cost of sales and SG&A growth (+14.1% YoY) outpacing revenue (+5.9% YoY), indicating negative operating leverage. The DuPont 5-factor view is distorted: EBIT margin is 23.4%, but the interest burden (EBT/EBIT) at 2.583 reflects extraordinary income inflating EBT, not financing effects. The tax burden at 0.690 is in a normal range. The margin compression appears linked to LABO profitability pressure and higher overheads; without structural cost relief or price/mix improvements, the prior-year operating margin level looks unlikely to be quickly regained. SG&A growth exceeding revenue is a key concern, suggesting cost discipline and productivity actions are needed to restore operating leverage.

Growth Assessment

Revenue grew 5.9% YoY to 182.53bn JPY, with both LABO (+7.1% YoY) and Products & Others (+5.3% YoY) contributing. However, operating income declined 20.3% YoY as gross profit fell despite higher sales, indicating weaker unit economics and/or adverse mix. Products & Others remains the profit engine with a 36.2% margin, while LABO’s margin fell to 11.2%, significantly reducing consolidated operating leverage. Ordinary income tracked operating profit, signaling limited recurring non-operating offsets. Net income growth (+108.5% YoY) is entirely non-recurring, driven by a large gain on sale of investment securities. The business retains ample capacity for organic growth investment given the cash-rich balance sheet. Near-term growth quality hinges on stabilizing LABO margins and normalizing inventory turns (66 days). Execution on cost control and pricing in LABO, coupled with continued strength in Products, should determine whether full-year operating guidance is achievable.

Financial Health

Liquidity is robust: current ratio 339.9% and quick ratio 306.3%, supported by 132.83bn JPY in cash and deposits versus 52.35bn JPY of current liabilities. Solvency is conservative with D/E at 0.33x and Debt/Capital at 2.3%, while interest coverage is a very strong 313.9x. Maturity profile risk is low: interest-bearing debt totals 5.63bn JPY against substantial cash, and current liabilities are well covered by liquid assets. Asset retirement obligations stand at 9.72bn JPY, representing a meaningful 12.1% of total liabilities, which should be incorporated into long-term cash planning. Investment securities were largely liquidated, de-risking the balance sheet and boosting cash. Working capital is positive (125.59bn JPY) with manageable receivables and payables, though inventories increased 49.2% YoY, warranting monitoring.

Notable B/S Changes

Cash & Deposits: +91.56bn (+218.3%) - Proceeds from sale of investment securities bolstered liquidity. Investment Securities: -42.72bn (-98.1%) - Portfolio largely liquidated; de-risking but removes financial income optionality. Inventories: +5.81bn (+49.2%) - Stock build raises working capital needs; monitor demand alignment. Long-term Loans: -3.80bn (-40.3%) - Deleveraging improves financial flexibility. Retained Earnings: +59.94bn (+33.8%) - Accumulation from strong net profit expands equity base.

Cash Flow Quality

Earnings quality for the period is skewed by the 67.63bn JPY extraordinary gain on sale of investment securities, which also aligns with the large decline in investment securities (−98.1% YoY) and the 218% increase in cash. Ordinary/operating earnings provide a better indicator of recurring performance than net income this quarter. Inventory days at 66 suggest working capital intensity has risen, potentially delaying cash conversion if not addressed. With minimal interest-bearing debt and substantial cash, the company has ample capacity to fund capex and dividends from internal resources. Monitoring the trajectory of inventories and receivables will be important to ensure cash conversion improves alongside any margin recovery.

Dividend Sustainability

The company declared a Q3 DPS of 40 JPY, implying a year-to-date payout ratio of approximately 14% versus YTD EPS of 279.64 JPY. Full-year guidance calls for DPS of 60 JPY against forecast EPS of 342.22 JPY, a payout ratio of roughly 17.5%, which is conservative and consistent with sustainable policy. The strong cash position and low leverage support dividend capacity even as operating margins recover. Given the non-recurring nature of this quarter’s net income, anchoring dividend affordability to operating cash generation and normalized earnings is appropriate; current balance sheet strength provides a substantial buffer.

Risk Assessment

Business risks include Segment concentration: KeePer LABO Operation accounts for 53.5% of revenue, and its margin fell to 11.2%, exposing consolidated earnings to LABO execution and demand variability, Margin pressure from higher costs and SG&A growth outpacing revenue, particularly in LABO, Demand sensitivity to consumer discretionary trends and weather conditions affecting car-coating service volumes (industry-specific), Inventory buildup (66 days) may reflect forecasting or demand normalization risk.

Financial risks include Elevated asset retirement obligations: 9.72bn JPY (12.1% of liabilities) increase long-term cash commitments, Working capital intensity rising due to higher inventories could delay cash conversion if sales slow, Reduced investment securities balance lowers financial income diversification and marketable buffer, increasing reliance on operating performance.

Key concerns include Guidance execution risk: revenue and operating income progress (69% and 59%) lag typical Q3 run-rate while net income is ahead on one-off gains, Earnings quality: large extraordinary gain drives headline net profit, masking a 20% YoY decline in operating income, SG&A discipline: +14% YoY vs +6% revenue indicates negative operating leverage that must be reversed.

Investment Implications

Key takeaways include Core operations under pressure: operating margin fell ~770 bps YoY despite 5.9% sales growth, Net income surge is non-recurring, driven by 67.63bn JPY gain on securities, Products & Others is the core profit engine (31.57bn JPY OI; 36.2% margin), while LABO requires margin repair, Balance sheet strength (cash 132.83bn JPY; low debt) provides resilience and investment capacity, Inventory days at 66 and high ARO share of liabilities underscore cash planning and execution focus.

Metrics to watch include LABO segment operating margin trajectory and same-store/service volume indicators, Gross margin recovery and SG&A growth vs revenue (operating leverage), Inventory days and receivables turnover (cash conversion), Progress vs full-year operating income guidance (target 72.87bn JPY), Ordinary income vs net income gap narrowing as extraordinary support fades.

Regarding relative positioning, Within Japan small-mid cap consumer services/auto care peers, KeePer技研 offers superior balance sheet strength and a high-margin product segment but currently trails on operating momentum due to LABO margin compression; normalization of core margins is critical to re-align earnings quality with headline profitability.